- What is Tiltan Pharma's primary focus?
- Tiltan Pharma is a biopharmaceutical company focused on developing anti-angiogenic and immune modulatory platforms for cancer treatment.
- What is the status of Tiltan Pharma?
- Tiltan Pharma is currently inactive, having ceased operations in September 2019.
- When was Tiltan Pharma founded?
- Tiltan Pharma was founded in January 2006.
- What is Tiltan Pharma's leading product?
- Tiltan Pharma's leading product is TL-118, an oral drug combination with anticancer, anti-angiogenic, and immune modulatory properties, which repurposes four approved drugs.
- What clinical trials was Tiltan Pharma conducting?
- Tiltan Pharma was conducting a randomized, open-label phase-IIb clinical trial for TL-118 in metastatic pancreatic cancer under an FDA-approved investigational new drug application. This trial was being conducted in Israel, Eastern Europe, and through US investigator-initiated studies.
- How much funding did Tiltan Pharma raise?
- Tiltan Pharma raised a total of $1,500,000.
- Which investor participated in Tiltan Pharma's funding round?
- Integra Holdings participated in Tiltan Pharma's funding round in February 2014.
- What is the employee count for Tiltan Pharma?
- Tiltan Pharma had an employee count in the 11-50 range.
- Who are the co-founders of Tiltan Pharma?
- The co-founders of Tiltan Pharma are Yigal Stav, who served as Co-founder & CEO, and Prof. Shmuel (Muli) Ben-Sasson, who served as Co-founder & CSO.
